peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

glycopeptide antibiotic

Teicoplanin

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

Teicoplanin was included as an exposure (antibiotic substance) in a retrospective multicountry consumption analysis evaluating associations between generic market entry and antibiotic use over 2012–2021.

Sources for this introduction: [1]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

How does it work?

Target, response, and disposition.

Mechanism

Teicoplanin was included as an exposure (antibiotic substance) in a retrospective multicountry consumption analysis evaluating associations between generic market entry and antibiotic use over 2012–2021.

Sources[1]pubmedImpact of generic market entry on the consumption of last-resort antibiotics in six European countries.Substances included daptomycin, linezolid, tigecycline, teicoplanin, and moxifloxacin.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Substances included daptomycin, linezolid, tigecycline, teicoplanin, and moxifloxacin.”

    Impact of generic market entry on the consumption of last-resort antibiotics in six European countries. · METHODS

    pubmed:42336237:eb9b973f4722:eb9b973f4722

What has been studied?

What the evidence says.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, identity, interaction, regulatory, safety

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Impact of generic market entry on the consumption of last-resort antibiotics in six European countries. ↗

    pubmed · published 2026-09-01 · retrieved 2026-08-26T08:42:26Z

Publication history and provenance

Version 2 · Automated assessment · 2026-08-26T08:42:26Z

069e87562b3e63dc43029bb4c0c7b36e7b4544f2d663bc096877e481189c2868